Please assess the completion status of the following clinical trial:

Trial Title: Intra-articular Polyacrylamide Hydrogel in Gonarthrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women above 50 years;~* A signed Patient Informed Consent Form by the study participant;~* Verified knee osteoarthritis in accordance with the ACR (knee pain combined with one of the following signs: age above 50 years, knee crepitus or morning joint stiffness lasting for less than 30 minutes combined with radiologic signs of knee osteoarthritis);~* Kellgren Lawrence radiological grade II-III knee osteoarthritis with the predominant involvement of the medial tibiofemoral region of the knee joint;~* Completion of participation in clinical study protocol IA / PAAG-SI / OA / 2019 in the NOLTREX ™ medical device group with the completion of all 5 visits (25 weeks)~Exclusion Criteria:~1. Pregnancy and breastfeeding;~2. History of trauma or surgery on the target knee joint;~3. Instability of the target knee joint;~4. Microcrystalline arthropathies (according to the history and taking into account clinical manifestations);~5. History of systemic inflammatory diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.);~6. Seronegative spondyloarthritis and reactive arthritis;~7. Increased rheumatoid factor;~8. Increased uric acid \> 360 µmol/l;~9. Intra-articular injection into the target knee joint:~   * hyaluronates - within 12 months prior to patient enrollment in the study;~  * other synovial fluid endoprostheses (except for NOLTREX™ in the IA/PAAG- SI/OA/2019 study) within 24 months;~  * glucocorticoids - within 1 month before enrollment in the study;~  * NSAIDs - intra-articular injection at any time in the history.~10. Systemic pain medications (NSAIDs, opioid analgesics) within 1 week prior to Visit 0;~11. Effusion in the target joint;~12. The presence of inflammation or infection in the target joint, synovitis;~13. The need for continuous use of glucocorticoids in any dosage form;~14. Use of paracetamol within 48 hours prior to Visit 0;~15. A positive blood test result for one or more of the following infections: HIV, hepatitis B and C, syphilis;~16. Severe liver disease, defined as an increase in one of the following: ALT, AST, alkaline phosphatase, total bilirubin, GGT more than 3 times the upper limit of normal;~17. Kidney disease with a glomerular filtration rate as assessed by the Cockcraft-Gault formula less than 60 mL/min/1.73 m2 (stages III-V chronic kidney disease \[CKD\]);~18. Clinical manifest coxarthrosis;~19. Severe decompensated chronic or acute diseases and other conditions or other causes that, in the investigator's opinion, may prevent the patient from participating in the study or affect the study results ;~20. Participation in any other clinical study other than study IA/PAAG-SI/OA/2019 within 90 days prior to enrollment in the study.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- hydrous biopolymer with silver ions Argiform (Type: OTHER): Sixty-seven patients were screened for the study; 2 of them were screening failures, therefore, 65 patients were randomized to participate in the study, who were conventionally divided into subgroups:~* Group A included 5 patients. Patients in group A received 2 courses of therapy: both within IA/PAAG-SI/OA/2019 study and at Visit 1 (and as indicated at Visit 2) of the IA/PAAG-SI/OA/2020 study.~* Group B - 43 patients. Patients in group B also received 2 courses of therapy: both within IA/PAAG-SI/OA/2019 study and at Visit 3 (and as indicated at Visit 4) of the IA/PAAG-SI/OA/2020 study.~* Group C - 17 patients. Group C included patients who received only one course of injections in the placebo-controlled study IA/PAAG-SI/OA/2019. There were no early withdrawals from the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).